Lundgaard, Agnete T. http://orcid.org/0000-0001-7447-6560
Westergaard, David http://orcid.org/0000-0003-0128-8432
Röder, Timo http://orcid.org/0000-0001-6841-4056
Burgdorf, Kristoffer S. http://orcid.org/0000-0001-5814-6844
Larsen, Margit H. http://orcid.org/0000-0003-1679-5103
Schwinn, Michael http://orcid.org/0000-0002-6151-369X
Thørner, Lise W. http://orcid.org/0000-0003-4391-4956
Sørensen, Erik http://orcid.org/0000-0002-5002-9077
Nielsen, Kaspar R. http://orcid.org/0000-0003-4406-9643
Hjalgrim, Henrik http://orcid.org/0000-0002-4436-6798
Erikstrup, Christian http://orcid.org/0000-0001-6551-6647
Kjerulff, Bertram D. http://orcid.org/0000-0001-9953-9521
Hindhede, Lotte http://orcid.org/0000-0001-9439-3906
Hansen, Thomas F. http://orcid.org/0000-0001-6703-7762
Nyegaard, Mette http://orcid.org/0000-0003-4973-8543
Birney, Ewan http://orcid.org/0000-0001-8314-8497
Stefansson, Hreinn
Stefánsson, Kári
Pedersen, Ole B. V. http://orcid.org/0000-0003-2312-5976
Ostrowski, Sisse R. http://orcid.org/0000-0001-5288-3851
Rossing, Peter http://orcid.org/0000-0002-1531-4294
Ullum, Henrik http://orcid.org/0000-0001-7306-9058
Mortensen, Laust H. http://orcid.org/0000-0002-6399-495X
Vistisen, Dorte http://orcid.org/0000-0001-5045-5351
Banasik, Karina http://orcid.org/0000-0003-2489-2499
Brunak, Søren http://orcid.org/0000-0003-0316-5866
,
Funding for this research was provided by:
Novo Nordisk
Astellas Pharma
AstraZeneca
Bayer
Abbott Laboratories
Novo Nordisk Fonden (NNF14CC0001, NNF17OC0027594, NNF17OC0027812, NNF17OC0027864)
Boehringer Ingelheim
Sanofi
Merck KGaA
Copenhagen University
Article History
Received: 15 December 2023
Accepted: 3 June 2024
First Online: 30 July 2024
Data availability
: Data cannot be publicly shared but may be made available upon request. Requests should be directed to the corresponding author. Approval is contingent on adherence to Danish law and may be subject to restrictions.
: Open access funding provided by Copenhagen University. ATL, DW, TR, KB and SB were supported by the Novo Nordisk Foundation (grants NNF14CC0001 and NNF17OC0027594). BDK was supported by the Novo Nordisk Foundation Challenge Programme (grant NNF17OC0027864). LHM acknowledges support from the Novo Nordisk Foundation (grants NNF17OC0027812 and NNF17OC0027594). DV has received research grants from Bayer A/S, Sanofi A/S, Novo Nordisk A/S, and Boehringer Ingelheim; all fees were given to the Steno Diabetes Center Copenhagen. PR reports receipt of honoraria to Steno Diabetes Center Copenhagen for education and consultancy from Abbott, AstraZeneca, Bayer A/S, Boehringer Ingelheim, Lexicon Inc, Novartis and Novo Nordisk A/S.
: DV holds shares in Novo Nordisk A/S and is employed at Novo Nordisk A/S (current affiliation). SB holds shares in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S and Lundbeck A/S, and managing board memberships in Proscion A/S and Intomics A/S. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: ATL, DV, DW, HU, KB, LHM and SB conceived and designed the study. ATL, BDK, the DBDS Genomic Consortium, LH, LHM, MHL and TR carried out the analysis. ATL, DV, KB, TR and SB drafted the manuscript. SB is responsible for the integrity of the work as a whole. All authors acquired and interpreted the data, critically revised the paper, and had final responsibility for the decision to submit for publication.